News | February 25, 2026
BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Subscribe To Our Newsletter & Stay Updated
